Login
From:
Drug Discovery and Development
(Uncensored)
subscribe
Dupixent bests Xolair in first head-to-head respiratory trial
https://www.drugdiscoverytrends.com/dupixent-bests-xolair-in-first-head-to-head-respiratory-trial-4-takeaways/
links
backlinks
Tagged with:
pulmonology
Sanofi and Regeneron have announced that the monoclonal antibody outperformed Xolair (omalizumab) on all primary and secondary efficacy endpoints in a phase 4 study focused on patients with chronic rhinosinusitis.
Roast topics
Find topics
Find it!
